17β-Estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1

Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF‐κB signals

“…The contradictory observations might be due to the use of agonists of different specificities (i.e. estrogen, tamoxifen, and bisphenol A) in their studies (Jiang et al., 2013b; Pandey et al., 2009; Yan et al., 2013; Yu et al., 2014) as compared to the use of the specific agonist G‐1 in our study. Therefore in cancer cells expressing the classical ERα and estrogen related receptor α (ERRα), the pro‐migration effects might be exerted and stimulated via ERα (Park et al., 2008; Ye et al., 2010) or ERRα (Lam et al., 2014; Sailland et al., 2014), rather than the GPER pathway.…”

GPER/ERK&AKT/NF-κB pathway is involved in cadmium-induced proliferation, invasion and migration of GPER-positive thyroid cancer cells

“…* p < 0.05, compared with treatment at 0 min. Cd facilitates nuclear translocation of NF-κB, expression of cyclin A and D1, and secretion 290of IL-8 in WRO and FRO cells like E2 and G1 291Our previous study has shown that GPER regulates transcriptional activity of NF-κB upon estrogen 292 stimulation through ERK and AKT signaling pathway(Jiang et al, 2013). NF-κB is one of the 293 redox-sensitive transcription factors.…”

Analysis of GPER1, CXCR1 and HER-2 Immuno Expression in Follicular Thyroid Lesions and their Possible Role as Diagnostic Markers

“…This leads to production of several downstream signaling molecules that are associated with cancer cell proliferation, invasion, metastasis and resistance to therapy [31]. CXCR1 was found to be involved in EGFR activation through interaction with GPER1 especially in estrogen negative cancer [32]. It was reported that GPER1 protein expression was higher in endometrial carcinoma, ovarian carcinomas and lung tumors, when compared with their normal or benign tissues [33][34][35].On the contrary; GPER1was positive in all samples of normal breast, while in carcinoma cases only 42% were positive [36].…”